Regulus Therapeutics

Type: Company
Name: Regulus Therapeutics
First reported 11 mins ago - Updated 11 mins ago - 1 reports

Regulus Initiates ATHENA Natural History of -2-

All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which ... [Published Scottrade - 11 mins ago]
First reported 15 mins ago - Updated 13 mins ago - 2 reports

Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients

LA JOLLA, Calif.The data collected from the ATHENA study will provide much needed information about the changes in renal function over time in Alport syndrome patients, which will inform future clinical development plans of Regulus' RG-012, a single stranded, ... [Published Industrial Info Financials - 13 mins ago]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Regulus Therapeutics major shareholder Alnylam Pharmaceuticals, Inc. Sells 8,900 Shares (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) major shareholder Alnylam Pharmaceuticals, Inc. unloaded 8,900 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $7.85, for a total transaction ... [Published American Banking News - Forex - Sep 13 2014]
First reported Sep 06 2014 - Updated Sep 06 2014 - 1 reports

Insider Selling: Isis Pharmaceuticals Inc Sells 10,050 Shares of Regulus Therapeutics Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 10,050 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $7.07, for a total transaction of $71,053.50. The transaction ... [Published American Banking News - Sep 06 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

5 Breakout Stocks Under $10 Set to Soar

aDELAFIELD, Wis. (Stockpickr) --aThere isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline ... [Published The Street Latest - Sep 05 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Regulus Therapeutics major shareholder Unloads $15,795 in Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) major shareholder Alnylam Pharmaceuticals, Inc. sold 2,250 shares of Regulus Therapeutics stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.02, for a total transaction ... [Published American Banking News - Forex - Aug 16 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

REGULUS THERAPEUTICS : Reports Second Quarter 2014 Financial Results and Recent Highlights

By a News Reporter-Staff News Editor at Biotech Week -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, reported financial results and highlights for ... [Published 4 Traders - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Net loss widens for Regulus

17:12 ET | About: Regulus Therapeutics (RGLS)Regulus Therapeutics (RGLS -0.6%) Q2 results: Revenues: $0.7M (-84.5%); Net Loss: ($12.0M) (-65.2%); Loss Per Share: ($0.29) (-45.0%); Quick Assets: $103.5M (-9.2%).No financial guidance given. ... [Published Seeking Alpha - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Regulus Therapeutics Receives Average Recommendation of “Buy” from Brokerages (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) has received an average rating of "Buy" from the nine analysts that are currently covering the company, . One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation ... [Published American Banking News - Aug 12 2014]
First reported Aug 09 2014 - Updated Aug 09 2014 - 1 reports

Insider Selling: Regulus Therapeutics Director Sells 1,850 Shares of Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc unloaded 1,850 shares of Regulus Therapeutics stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $6.80, for a total value of $12,580.00. The sale ... [Published American Banking News - Forex - Aug 09 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights

LA JOLLA, Calif., Aug. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for ... [Published PR Newswire: Financial Services - Aug 06 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Biotech CEOs Speak Out on JOBS Act Success

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and ... [Published I Am Biotech - Jul 31 2014]

Quotes

"Orphan diseases like Alport syndrome are poorly or incompletely understood and we believe that conducting a natural history study is an essential element to facilitate efficient clinical development. In the ATHENA study, we anticipate that prospectively measuring changes in GFR and other renal biomarkers should provide the clinical basis for the design of a Phase II study to monitor the therapeutic effect of RG-012 on the decline in renal function and time to end-stage renal disease in patients with Alport syndrome" said Paul Grint
...in renal function and time to end-stage renal disease in patients with Alport syndrome," said Paul Grint , M D , Chief Medical Officer of Regulus.  "The data from ATHENA will be important to the Alport syndrome patient community and Regulus' future success in treating the disease with RG-012, a key program under our 'Clinical Map Initiative'."
Neil W Gibson , Ph D , Chief Scientific Officer of Regulus, added, "We are very pleased with our recent scientific progress and hope to extend our good track record into the second half of 2014. We have several significant catalysts on the horizon by the end of the year, we have the opportunity to report our first human proof of concept results with a microRNA therapeutic, strengthen our focus on orphan diseases by advancing RG-012 toward the clinic, and expand our overall microRNA therapeutics pipeline with the nomination of a third candidate for clinical development."
...may be available as advancements in life sciences continue to develop at a swift pace," said Mark Benson, Director of Research, Wedbush Securities. "Our conference will address these issues and provide critical insights through sector specific deep dives, moderated management presentations, one-on-one meetings and informative panels comprised of industry experts."

More Content

All (47) | News (24) | Reports (0) | Blogs (23) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Regulus Initiates ATHENA Natural History of -2- [Published Scottrade - 11 mins ago]
Regulus Initiates ATHENA Natural History of Dis... [Published Industrial Info Financials - 13 mins ago]
Regulus Initiates ATHENA Natural History of Dis... [Published ADVFN India - 15 mins ago]
Alnylam to Webcast Presentation at Morgan Stanl... [Published Pharmacy Choice - Sep 17 2014]
Alnylam Presents New Pre-Clinical Data with -2- [Published Scottrade - Sep 16 2014]
Regulus Therapeutics major shareholder Alnylam ... [Published American Banking News - Forex - Sep 13 2014]
Insider Selling: Isis Pharmaceuticals Inc Sells... [Published American Banking News - Sep 06 2014]
5 Breakout Stocks Under $10 Set to Soar [Published The Street Latest - Sep 05 2014]
Alnylam to Webcast Presentation at Morgan Stanl... [Published Scottrade - Sep 03 2014]
Regulus Therapeutics major shareholder Unloads ... [Published American Banking News - Forex - Aug 16 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
REGULUS THERAPEUTICS : Reports Second Quarter 2... [Published 4 Traders - Aug 13 2014]
Alnylam to Host Additional Events in "RNAi Roun... [Published Pharmacy Choice - Aug 13 2014]
Net loss widens for Regulus [Published Seeking Alpha - Aug 12 2014]
Wedbush PacGrow Life Sciences Hosts Management ... [Published Nations Restaurant News - Aug 12 2014]
Regulus Therapeutics Receives Average Recommend... [Published American Banking News - Aug 12 2014]
Insider Selling: Isis Pharmaceuticals Inc Sells... [Published American Banking News - Forex - Aug 11 2014]
Insider Selling: Regulus Therapeutics Director ... [Published American Banking News - Forex - Aug 09 2014]
Regulus to Present at the Wedbush Life Sciences... [Published PR Newswire: Health - Aug 07 2014]
Regulus Reports Second Quarter 2014 Financial R... [Published PR Newswire: Financial Services - Aug 06 2014]
Regulus Enters Into New Collaboration Agreement... [Published PR Newswire: Health - Aug 05 2014]
Biotech CEOs Speak Out on JOBS Act Success [Published I Am Biotech - Jul 31 2014]
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - Jul 30 2014]
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
Regulus Announces Patent Grant from U.S. Patent... [Published PR Newswire: Policy & Public Interest - Jun 25 2014]
Regulus to Present at the Bank of America Merri... [Published PR Newswire: General Business - May 09 2014]
Regulus Reports First Quarter 2014 Financial Re... [Published PR Newswire: Financial Services - May 08 2014]
Regulus to Present at the Deutsche Bank 39th An... [Published PR Newswire: Health - Apr 30 2014]
Regulus Presents Positive Preclinical Data on m... [Published PR Newswire: Health - Apr 07 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus to Present at the Wedbush Life Sciences... [Published PR Newswire: Health - Aug 07 2014]
LA JOLLA, Calif., Aug. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., ...
Regulus Reports Second Quarter 2014 Financial R... [Published PR Newswire: Financial Services - Aug 06 2014]
LA JOLLA, Calif., Aug. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for ...
Regulus Enters Into New Collaboration Agreement... [Published PR Newswire: Health - Aug 05 2014]
LA JOLLA, Calif., Aug. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement ...
Biotech CEOs Speak Out on JOBS Act Success [Published I Am Biotech - Jul 31 2014]
Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and ...
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - Jul 30 2014]
LA JOLLA, Calif., July 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.